Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 28, 2022

Early PEG-Asparaginase Discontinuation in Young Adults With Acute Lymphoblastic Leukemia

Blood Advances


Additional Info

Disclosure statements are available on the authors' profiles:

Blood Advances
The impact of early PEG-asparaginase discontinuation in young adults with ALL: A post hoc analysis of the C10403 study
Blood Adv 2022 Oct 21;[EPub Ahead of Print], I Aldoss, J Yin, A Wall, K Mrózek, M Liedtke, D Claxton, MC Foster, FR Appelbaum, HP Erba, MR Litzow, MS Tallman, RM Stone, RA Larson, AS Advani, W Stock, SM Luger

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading